vTv Therapeutics (VTVT) Non-Current Debt (2014 - 2023)

vTv Therapeutics has disclosed Non-Current Debt across 10 years of filings, most recently posting $922000.0 for Q1 2023.

• Non-Current Debt for Q1 2023 came in at $922000.0, up 19.74% year-over-year; the trailing twelve-month figure through Mar 2023 was $922000.0 (up 19.74% YoY), and the FY2022 annual result was $684000.0, down 45.8% from the prior year.
• Non-Current Debt came in at $922000.0 for Q1 2023 at vTv Therapeutics, up from $684000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $4.5 million in Q1 2021 to a low of $684000.0 in Q4 2022.
• The 5-year median for Non-Current Debt is $2.3 million (2021), against an average of $2.2 million.
• Across the five-year window, Non-Current Debt slumped 88.59% in 2019 and soared 184.6% in 2020, its largest moves.
• vTv Therapeutics' Non-Current Debt stood at $2.6 million in 2019, then climbed by 10.38% to $2.9 million in 2020, then slumped by 56.04% to $1.3 million in 2021, then sank by 45.8% to $684000.0 in 2022, then jumped by 34.8% to $922000.0 in 2023.
• The last three Non-Current Debt figures came in at $922000.0 (Q1 2023), $684000.0 (Q4 2022), and $1.4 million (Q3 2022), per Business Quant data.